Lesions of the Peripheral Nervous System

  • Jerzy Hildebrand
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The identification of peripheral nervous lesions plays at least two important roles in the management of cancer patients: a) by allowing an earlier diagnosis of the underlying neoplasia and thus hastening its therapy, or b) by pointing to new locations of an already known malignancy and thereby determining its extent.


Brachial Plexus Small Cell Lung Carcinoma Meningeal Carcinomatosis Cranial Nerve Dysfunction Peripheral Nerve Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenberg HS, Deck MDF, Vikram B et al: Metastasis to the base of the skuli: Clinical findings in 43 patients. Neurology 1981 (31):530–537PubMedGoogle Scholar
  2. 2.
    Sandler SG, Tobin W, Henderson ES: Vincristine- induced neuropathy. Neurology 1969 (19):367–374PubMedGoogle Scholar
  3. 3.
    Whitaker JA, Griffith IP: Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. Br Med J 1977 (1):1251–1252CrossRefGoogle Scholar
  4. 4.
    Massey EW, Moore J and Schold SC: Mental neuropathy from systemic cancer. Neurology 1981 (31):1277–1281PubMedGoogle Scholar
  5. 5.
    Clouston PD, Sharpe DM, Corbett AJ et al: Perineural spread of cutaneous head and neck cancer. Arch Neurol 1990 (47):73–77PubMedGoogle Scholar
  6. 6.
    Turgman J, Braham J, Modan B and Goldhammer Y: Neurological complications in patients with malignant tumors of the nasopharynx. Europ Neurol 1978 (17):149–154PubMedCrossRefGoogle Scholar
  7. 7.
    Berger PS and Bataini JP: Radiation-induced cranial nerve palsy. Cancer 1977 (40):152–155PubMedCrossRefGoogle Scholar
  8. 8.
    Meyer JE and Wang CC: Carcinoma of nasopharynx. Factors influencing results of therapy. Radiology 1971 (100):385–388PubMedGoogle Scholar
  9. 9.
    Layzer RB: Neoplastic Diseases. In: Neuromuscular Manifestations of Systemic Disease. Davis Co, Philadelphia 1985, pp 258–259Google Scholar
  10. 10.
    Hepper NGG, Herskovic T, Witten DM et al: Thoracic inlet tumors. Ann Intern Med 1966 (64):979–989Google Scholar
  11. 11.
    Attar S, Miller JE, Satterfield J et al: Pancoat’s tumor: Irradiation or surgery? Ann Thorac Surg 1979 (28):578–586PubMedCrossRefGoogle Scholar
  12. 12.
    Batzdorf U and Brechner VL: Management of pain associated with the Pancoast’ syndrome. Ann J Surg 1979 (137):638–646CrossRefGoogle Scholar
  13. 13.
    Kori SH, Foley KM, and Posner JB: Brachial plexus lesions in patients with cancer: 100 cases. Neurology 1981 (31):45–50PubMedGoogle Scholar
  14. 14.
    Cascino TL, Kori S, Krol G, and Foley KM: CT of the brachial plexus in patients with cancer. Neurology 1983 (33):1553–1557PubMedGoogle Scholar
  15. 15.
    Bagley FH, Walsh JW, Cady B et al: Carcinomatous versus radiation-induced brachial plexus neuropathy in breast cancer. Cancer 1978 (41)2154–2157PubMedCrossRefGoogle Scholar
  16. 16.
    Thomas JE, Cascino TL, and Earle JD: Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology 1985 (35):1–7PubMedGoogle Scholar
  17. 17.
    Jaeckle KA, Young DF and Foley KM: The natural history of lumbosacral plexopathy in cancer. Neurology 1985 (35):8–15PubMedGoogle Scholar
  18. 18.
    Aho I, Sainio K: Late irradiation-induced lesions of the lumbosacral plexus. Neurology 1983 (33):953– 955PubMedGoogle Scholar
  19. 19.
    Hildebrand J: Peripheral neuropathy. In: Hildebrand J (ed) Neurological Adverse Reactions to Anticancer Drugs. European School of Oncology Mongraph Series. Springer-Verlag, Berlin 1991 pp 93–99Google Scholar
  20. 20.
    Hildebrand J and Coers C: The neuromuscular function in patients with malignant tumors. Brain 1967 (90):67–82PubMedCrossRefGoogle Scholar
  21. 21.
    Krendel DA, Albright RE and Graham DG: Infiltrative polyneuropathy due to acute monoblasts leukemia in hematologic remission. Neurology 1987 (37):474– 477PubMedGoogle Scholar
  22. 22.
    Roelofs Rl, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984 (34):934–938PubMedGoogle Scholar
  23. 23.
    Lipton RB, Aptel SC, Dutcher JP et al: Taxol produces a predominantly sensory neuropathy. Neurology 1989 (39):368–373PubMedGoogle Scholar
  24. 24.
    Denny-Brown D: Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psychiat 1948 (11):73–87PubMedCrossRefGoogle Scholar
  25. 25.
    Lisak RP, Mitchell M, Zweiman B et al: Guillain-Baré syndrome and Hodgkin’s disease. Three cases with immunologic studies. Ann Neurol 1977 (1):72–78Google Scholar
  26. 26.
    Hildebrand J, Kenis Y: Additive toxicity of vincristine and other drugs for the peripheral nervous system. Acta Neurol Belg 1971 (71):486– 491PubMedGoogle Scholar
  27. 27.
    Jackson DV, Wells HB, Atkins JN et al: Amelioration of vincristine neurotoxicity by glutamic acid. Ann J Med 1988 (84):1016–1022.CrossRefGoogle Scholar
  28. 28.
    Favaro G, Di Gregorio F, Panozzo C and Fiori MG: Ganglioside treatment of vincristine-induced neuropathy. An electrophysiologic study. Toxicology 1988, 49: 325–329PubMedCrossRefGoogle Scholar
  29. 29.
    Menesini MG, Chen JS, Calissano P and Levi- Montalcini R: Nerve growth factor prevents vinblastine destructive effects on sympathetic ganglia in newborn mice. Proc Natl Acad Sei 1977 (74):5559–5563CrossRefGoogle Scholar
  30. 30.
    Apfel SC, Lipton RB, Arezzo JC and Kessler JA: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991 (29):87–90PubMedCrossRefGoogle Scholar
  31. 31.
    Apfel SC, Arezzo JC, Lipson LA and Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992 (31):76–80PubMedCrossRefGoogle Scholar
  32. 32.
    Gerritsen van der Hoop R, Vecht CJ, Van der Burg MEL et al: Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer. N Engl J Med 1990 (322):89–94CrossRefGoogle Scholar
  33. 33.
    Castellanos AM, Glass JP, Yung WKA: Regional nerve injury after intra-arterial chemotherapy. Neurology 1987 (37):834–837PubMedGoogle Scholar
  34. 34.
    Oh SJ: Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome. Muscle & Nerve 1989 (12):464–469CrossRefGoogle Scholar
  35. 35.
    Ongeboer de Visser BW, Boven E, and Ten Bokkel- Huinink WB: Lambert-Eaton syndrome: Electrophysiological normalization during chemotherapy. Clin Neurol Neurosurg 1979 (81):235–240CrossRefGoogle Scholar
  36. 36.
    Jenkyn LR, Brooks PL, Forcier et al: Remission of Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy. Cancer 1980 (46):1123–1127PubMedCrossRefGoogle Scholar
  37. 37.
    Clamon GH, Evans WK, Sheperd FA et al: Myasthenic syndrome and small cell carcinoma of the lung. Variable response to antineoplastic therapy. Arch Intern Med 1984 (144):999–1000Google Scholar
  38. 38.
    O’Neil JH, Murray NMF and Newsom-Davis J: The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988 (111): 577–596CrossRefGoogle Scholar
  39. 39.
    Oh SJ and Kim KW: Guanidine hydrochloride in the Lambert-Eaton syndrome. Electrophysiological improvement. Neurology 1973 (23):1084–1090Google Scholar
  40. 40.
    McEvoy KM, Windeback AJ, Daube JR and Low PA: 3, 4-Diaminopyridine in the treatment of Lambert- Eaton myasthenic syndrome. N Engl J Med 1989 (321):1567–1571PubMedCrossRefGoogle Scholar
  41. 41.
    Lundh H, Nilson O and Rosen I: Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984 (34):1324–1330PubMedGoogle Scholar
  42. 42.
    Streib EW and Rothner AD: Eaton-Lambert myasthenic syndrome: Long-term treatment of three patients with prednisolone. Ann Neurol 1981 (0):448–453CrossRefGoogle Scholar
  43. 43.
    Newson-Davis J and Murray NMF: Plasma exchange and immunodepressive drug treatment in the Lambert-Easton myasthenic syndrome. Neurology 1984 (34):480–485Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Jerzy Hildebrand
    • 1
  1. 1.Service de NeurologieHôpital ErasmeBrusselsBelgium

Personalised recommendations